Barclays »

Context Therapeutics shares owned by Barclays

Quarter-by-quarter ownership of Context Therapeutics (CNTX) shares owned by Barclays from 13F filings

Historical chart of Barclays investment in Context Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Context Therapeutics held by Barclays consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Context Therapeutics by Barclays

Quarter filed Position value Share count Share price at filing
2025-09-30 $162 167 0.97

More positions owned by Barclays

Microsoft Corporation (MSFT)
SPDR S&ampP 500 ETF TR Fund (SPY)
Invesco Qqq Tr Fund (QQQ)
NVIDIA Corporation (NVDA)
Ishares Tr Fund (IWM)
Apple (AAPL)
Tesla Opt Put Option (TSLA)
Amazon Opt Call Option (AMZN)
Alphabet Opt Call Option (GOOGL)
Broadcom Opt Call Option (AVGO)
Facebook Inc cl a (META)
Ishares Tr Opt Call Option (HYG)
JPMorgan Chase & Co. (JPM)
Alphabet Opt Put Option (GOOG)
Berkshire Hathaway Inc Del Opt Put Option (BRK.B)

View all positions for Barclays

Top funds holding Context Therapeutics

MPM Oncology Impact Management
Avidity Partners Management
Deep Track Capital
Nextech Invest
Blue Owl Capital Holdings
Dr. Jeffrey R. Jay, M.D.
Franklin Resources
Vanguard Group
Blackstone Group
Alyeska Investment Group
Nantahala Capital Management
Sio Capital Management
BlackRock
Geode Capital Management
Affinity Asset Advisors

View all funds holding Context Therapeutics